Sarah E. Garnish

Sarah E. Garnish

Auto-generated profile, based on publicly available information

Sarah E. Garnish

The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2021 in Science Signaling
Verified
Journal Article
Closed access
PDF file
ASAndré L. Samson
André L. Samson
SGSarah E. Garnish
Sarah E. Garnish
JHJoanne Hildebrand
Joanne Hildebrand
JMJames M. Murphy
James M. Murphy
Signaling events in distinct subcellular locations determine whether MLKL mediates necroptosis.

28 May 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
ECEmma Tovey Crutchfield
Emma Tovey Crutchfield
SGSarah E. Garnish
Sarah E. Garnish
JHJoanne Hildebrand
Joanne Hildebrand
Necroptosis is an inflammatory form of lytic programmed cell death that is thought to have evolved to defend against pathogens. Genetic deletion of the terminal effector protein—MLKL—shows no overt phenotype in the C57BL/6 mouse strain under conventional laboratory housing conditions. Small molecules that inhibit necroptosis by targeting the kinase activity of RIPK1, one of the main upstream conduits to MLKL activation, have shown promise in several murine models of non-infectious disease and in phase II human clinical trials. This has triggered in excess of one billion dollars (USD) in investment into the emerging class of necroptosis blocking drugs, and the potential utility of targeting the terminal effector is being closely scrutinised. Here we review murine models of disease, both genetic deletion and mutation, that investigate the role of MLKL. We summarize a series of examples from several broad disease categories including ischemia reperfusion injury, sterile inflammation, pathogen infection and hematological stress. Elucidating MLKL’s contribution to mouse models of disease is an important first step to identify human indications that stand to benefit most from MLKL-targeted drug therapies.

15 May 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
JHJoanne Hildebrand
Joanne Hildebrand
MKMaria Kauppi
Maria Kauppi
IMIan J. Majewski
Ian J. Majewski
ZLZikou Liu
Zikou Liu
ACAllison Cox
Allison Cox
JSJohn Silke
John Silke
SUMMARY: We have isolated a mouse strain with a single missense mutation in the gene encoding MLKL, the essential effector of necroptotic cell death. The resulting substitution lies within the two-helix ‘brace’ and confers constitutive, RIPK3 independent, killing activity to MLKL. Mice homozygous for Mlkl D139V develop lethal inflammation within days of birth, implicating the salivary glands and pericardium as hotspots for necroptosis and inflammatory infiltration. The normal development of Mlkl D139V homozygotes until birth, and the absence of any overt phenotype in heterozygotes provides important in vivo precedent for the capacity of cells to clear activated MLKL. These observations offer an important insight into the potential disease-modulating roles of three common human MLKL polymorphisms that encode amino acid substitutions within or adjacent to the brace region. Compound heterozygosity of these variants is found at up to 12-fold the expected frequency in patients that suffer from a pediatric autoinflammatory disease, CRMO.